Brian Drazba Net Worth

The estimated Net Worth of Brian G. Drazba is at least $956 mil dollars as of 19 December 2019. Mr. Drazba owns over 12,500 units of MEI Pharma Inc stock worth over $113,250 and over the last 10 years he sold MEIP stock worth over $0. In addition, he makes $842,612 as Chief Financial Officer y Secretary at MEI Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Drazba MEIP stock SEC Form 4 insiders trading

Brian has made over 1 trades of the MEI Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of MEIP stock worth $20,000 on 19 December 2019.

The largest trade he's ever made was buying 12,500 units of MEI Pharma Inc stock on 19 December 2019 worth over $20,000. On average, Brian trades about 1,042 units every 0 days since 2014. As of 19 December 2019 he still owns at least 37,500 units of MEI Pharma Inc stock.

You can see the complete history of Mr. Drazba stock trades at the bottom of the page.

Brian Drazba biography

Brian G. Drazba CPA serves as Chief Financial Officer, Secretary of the Company. Mr. Drazba has more than 25 years of financial management experience in the healthcare industry. Previously, he served as Vice President of Finance and Chief Financial Officer of Heron Therapeutics, Inc., a commercial-stage biotechnology company, from October 2013 to March 2017. From 2009 to 2012, he was Vice President of Finance and Chief Accounting Officer for ISTA Pharmaceuticals, a commercial-stage pharmaceutical company. ISTA Pharmaceuticals was acquired by Bausch + Lomb in June 2012. From 1992 to 2009, Mr. Drazba held various positions of increasing responsibility within Insight Health Corp., most recently as Senior Vice President and Chief Accounting Officer. He began his career at Arthur Andersen & Co., a public accounting firm. Mr. Drazba is a licensed Certified Public Accountant (inactive) in California and received a B.A. degree in Accounting from the University of San Diego.

What is the salary of Brian Drazba?

As the Chief Financial Officer y Secretary of MEI Pharma Inc, the total compensation of Brian Drazba at MEI Pharma Inc is $842,612. There are 3 executives at MEI Pharma Inc getting paid more, with Daniel Gold having the highest compensation of $1,854,410.

How old is Brian Drazba?

Brian Drazba is 58, he's been the Chief Financial Officer y Secretary of MEI Pharma Inc since 2017. There are 9 older and 4 younger executives at MEI Pharma Inc. The oldest executive at MEI Pharma Inc is Kevan Clemens, 75, who is the Independent Director.

What's Brian Drazba's mailing address?

Brian's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.

Insiders trading at MEI Pharma Inc

Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... y Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.

What does MEI Pharma Inc do?

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.

Complete history of Mr. Drazba stock trades at Heron Therapeutics Inc y MEI Pharma Inc

MEI Pharma Inc executives and stock owners

MEI Pharma Inc executives and other stock owners filed with the SEC include:

• Daniel Gold,
  President, Chief Executive Officer, Director
• David Urso,
  Chief Operating Officer, General Counsel
• Dr. Daniel P. Gold,
  Pres, CEO & Director
• Brian Drazba,
  Chief Financial Officer, Secretary
• David M. Urso B.A., Esq., J.D.,
  COO & Gen. Counsel
• Robert Mass,
  Chief Medical Officer
• Brian G. Drazba B.A., CPA, CPA,
  CFO & Sec.
• Dr. Richard G. Ghalie,
  Chief Medical Officer
• Dr. Robert D. Mass,
  Strategic Advisor
• Charles Baltic,
  Independent Director
• Nicholas Glover,
  Independent Director
• Kevan Clemens,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Tamar Howson,
  Independent Director
• Cheryl Cohen,
  Director
• Brian Powl,
  Senior Vice President of Marketing
• Tina Clark Beamon Esq., J.D.,
  Chief Compliance Officer
• Dr. Karen E. Potts Ph.D.,
  Sr. VP of Regulatory Affairs
• Dr. Ofir Moreno,
  Sr. VP of Pharmaceutical Sciences
• Jamie A. Tereschuck,
  VP of HR
• David A. Walsey J.D., L.L.M.,
  VP of IR & Corp. Communications
• Leaf Ventures Ii, L.P.New L...,
  
• Ventures V, Llc Vivo,
  
• Leah Rush Cann,
  Director
• Thomas M. Zech,
  Chief Financial Officer
• William Dodge Rueckert,
  Director
• Ventures Vii, Llc Vivo,
  
• Christine Anna White,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Ventures Vii, Llc Vivo Vent...,
  
• Josiah T El Coronado Holdin...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Josiah T Austin,
  10% owner
• Bryan Williams,
  Director
• Ltd Novogen,
  10% owner
• Sujay Kango,
  
• Richard G Ghalie,
  Chief Medical Officer
• Thomas C Reynolds,
  
• Funds Management Lp Anson A...,
  
• Funds, Lp Cable Car Capital...,
  
• Steven D Wood,
  
• James P Flynn,